Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case–control study

详细信息    查看全文

• 作者：Yuxing Zhang (1)
  Li Liu (2)
  Yingchun Tang (1)
  Chao Chen (1)
  Qian Wang (1)
  Jun Xu (1)
  Chao Yang (1)
  Xiaoping Miao (2)
  Sheng Wei (2) ws2008cn@gmail.com
  Jigui Chen (1) chenjigui@sina.com
  Shaofa Nie (2)
• 关键词：TP53 – MDM2 – Polymorphism – Colorectal cancer
• 刊名：Molecular Biology Reports
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：39
• 期：10
• 页码：9661-9668
• 全文大小：203.7 KB
• 参考文献：1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
  2. de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4:769–780
  3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
  4. Wan DS (2009) Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng 28:897–902
  5. Marte B (2002) Cancer: super p53. Nature 420:279
  6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665
  7. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S (2009) Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature 460:1132–1135
  8. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365
  9. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, Kato T, Tajima K (2002) No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 181:81–85
  10. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G (2007) Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 37:385–390
  11. Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S (2009) Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog 48:790–800
  12. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698
  13. Levav-Cohen Y, Haupt S, Haupt Y (2005) MDM2 in growth signaling and cancer. Growth Factors 23:183–192
  14. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602
  15. Xu B, Xu Z, Cheng G, Min ZC, Mi Y, Zhang ZZ, Tao J, Li PC, Wang ML, Tang JL, Zhang ZD, Zhang W, Wu HF, Feng NH, Hua LX (2010) Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet 202:76–81
  16. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A (2001) High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98:581–584
  17. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310
  18. Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604
  19. Yap DB, Hsieh JK, Chan FS, Lu X (1999) MDM2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681–7689
  20. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:1001–1008
  21. Mo P, Wang H, Lu H, Boyd DD, Yan C (2010) MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem 285:26908–26915
  22. Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan ZM, Jenuwein T, Marine JC, Wright KL, Chen J (2010) MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J 29:2538–2552
  23. Barak Y, Juven T, Haffner R, Oren M (1993) MDM2 expression is induced by wild type p53 activity. EMBO J 12:461–468
  24. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83
  25. Ouban A, Dellis J, Salup R, Morgan M (2003) Immunohistochemical expression of MDM2 and p53 in penile verrucous carcinoma. Ann Clin Lab Sci 33:101–106
  26. Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M (1999) Clinical significance of MDM2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 56:239–247
  27. Shwe M, Chiguchi G, Yamada S, Nakajima T, Maung KK, Takagi M, Amagasa T, Tsuchida N (2001) P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas. J Med Dent Sci 48:113–119
  28. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7:979–987
  29. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 17:4668–4679
  30. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199
  31. Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI (2010) Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5:e10813
  32. Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC (2011) TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 38:4847–4853
  33. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S (2010) TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 19:1840–1847
  34. Cao X, Zhang T, Zhao Z, Zhao T (2012) MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol 31:354–358
  35. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28:1996–2001
  36. Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y (2011) TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka colorectal cancer study. Jpn J Clin Oncol 41:232–238
  37. Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A (2010) Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10:88
  38. Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, Verma Y, Phukan R, Mahanta J, Kataki AC, Kapur S, Saxena S (2010) Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 30:163–171
  39. Caceres DD, Quinones LA, Schroeder JC, Gil LD, Irarrazabal CE (2009) Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung 187:110–115
  40. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27:110–117
  41. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950–952
  42. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285–288
  43. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531–533
• 作者单位：1. Department of Surgery, The Eighth Hospital of Wuhan City, No. 1307 of Zhongshan Avenue, Wuhan, 430000 China2. Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No. 13 of Hangkong Road, Wuhan, 430000 Hubei, China
• ISSN：1573-4978

文摘

The murine double minute 2 protein (MDM2) and TP53 interact in regulating cell cycle, DNA repair and apoptosis process, which is crucial in carcinogenesis. Since functional variations in these two genes were shown to change gene expression and function, we hypothesized that potentially functional polymorphisms in these genes may contribute to colorectal cancer (CRC) susceptibility. A hospital-based case–control study consisting of 444 patients and 569 controls was conducted to explore the associations between TP53 Arg72Pro and MDM2 T309G and CRC risk in Chinese. The combined effect of TP53 Arg72Pro and MDM2 T309G was significant in a gene dose–response increasing CRC risk (trend test: P = 0.02). Individuals carrying 3 or more potential risk alleles had 1.78 times risk (95 % CI: 1.13–2.80) to develop CRC compared with individuals without potential risk allele. This increased cancer risk was more pronounced in smokers who carried 3–4 potential risk alleles (OR = 2.75, 95 % CI: 1.14–6.60) and in young subjects (OR = 2.05, 95 % CI: 1.08–3.88). The gene–gene interaction between TP53 Arg72Pro and MDM2 T309G may interact in carcinogenesis of CRC in Chinese, especially in smokers, and this kind of interaction is associated with onset age of CRC.